Breast cancer (BC) is a highly heterogeneous malignancy originating from mammary epithelial cells and remains a leading cause of cancer-related mortality worldwide, with ∼2.3 million new cases and over 665,000-670,000 deaths annually. The disease is driven by complex molecular mechanisms, including hormone receptor signaling, genetic mutations (e.g., TP53, BRCA), and HER2 pathways. Advances in molecular classification have enabled the identification of distinct subtypes, including luminal A, luminal B, HER2-positive (HER2+) subtype, and triple-negative breast cancer (TNBC), each requiring tailored therapeutic strategies. A systematic literature review was conducted covering studies published between 2012 and 2025 using databases including Scopus, ScienceDirect, SpringerLink, and Taylor & Francis. Relevant studies on breast cancer biology, diagnostics, nanomedicine, and therapeutic strategies were selected based on predefined inclusion and exclusion criteria to ensure data relevance and quality. The review highlights significant progress in breast cancer management, particularly in early detection through imaging and biomarker screening, and in treatment through targeted therapy, immunotherapy, and nanocarrier-based drug delivery systems. Nanomedicine approaches have demonstrated improved tumor targeting and potential reductions in systemic toxicity in preclinical and early clinical studies; however, most nanomedicine platforms remain under clinical evaluation. Challenges such as metastasis, disease recurrence, and therapeutic resistance remain major clinical challenges, particularly in metastatic triple-negative breast cancer (mTNBC). Although distant-stage TNBC has an approximately 15% 5-year relative survival rate, median overall survival in mTNBC has historically been reported at about 8-13 months and may extend to approximately 12-18 months in some contemporary cohorts. Recent advances, including immune checkpoint inhibitors, PARP inhibitors, and antibody-drug conjugates (ADCs), have modestly improved outcomes. Despite substantial advancements, breast cancer remains a major clinical challenge due to its heterogeneity and resistance mechanisms. Integration of molecular profiling, precision medicine, and nanotechnology-based therapeutic strategies offers promising avenues for improving diagnosis, treatment efficacy, and patient outcomes. Future research should focus on overcoming resistance, targeting the tumor microenvironment (TME), and enhancing personalized treatment approaches.

Remogliflozin is an inhibitor of sodium-glucose cotransporter 2 inhibitors (SGLT-2) protein and plays an important role in the treatment and management of type-2 diabetes mellitus. In this study, a selective isocratic method was developed and validated using liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) for the determination of remogliflozin in rat plasma. Acetonitrile with formic acid was used as a precipitating agent. Chromatographic separation was achieved by using X select CSH Fluorophenyl (150 mm x 4.6 mm, 3.5 µm) column and 0.1% formic acid in milli-Q water (20%) and acetonitrile (80%), v/v as a mobile phase for isocratic elution method. Flow rate and injection volume were maintained at 0.7 mL/min and 10 µL, respectively. The validated method was linear in the range of 15– 2009 ng/mL with the lower limit of quantification (LLOQ) of 18 ng/mL. Also, the method was precise with a % CV less than 5.75 and accuracy within ±10% of nominal concentration. The method is accurate, simple, precise, and suitable for its application in further bioequivalence and pharmacokinetic studies.